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ABSTRACT 
Background: There is little specific guidance on the implementation of cost-effectiveness modelling 
at the early stage of test development. The aim of this study was to review the literature in this field to 
examine the methodologies and tools that have been employed to date. 
Methods: A systematic review was conducted to identify relevant studies in established literature 
databases.  
Results: Five studies were identified and included for narrative synthesis. These studies revealed that 
there is no consistent approach in this growing field. The perspective of patients and the potential for 
value of information (VOI) to provide information on the value of future research is often overlooked. 
Test accuracy is an essential consideration, with most studies having described and included all 
possible test results in their analysis, and conducted extensive sensitivity analyses on important 
parameters. Headroom analysis was considered in some instances but at the early development stage 
(not the concept stage).  
Expert commentary: The techniques available to modellers that can demonstrate the value of 
conducting further research and product development (i.e. VOI analysis, headroom analysis) should 
be better utilized. There is the need for concerted efforts to develop rigorous methodology in this 
growing field to maximize the value and quality of such analysis.  
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1.0 INTRODUCTION 
Economic evaluation is a tool that decision makers typically use to compare competing 
interventions after having demonstrated their quality, safety and effectiveness [1], and 
identifies those that are cost-effective with respect to their costs and consequences 
[2,3].Decision maker may refer to an established institution such as The National Institute for 
Health and Care Excellence (NICE) in the UK, or any individual or group of individuals who 
have vested authority to use economic analysis to support decision making for example in a 
medical technology company. Test evaluation ‘lags behind’ and differs from the evaluation of 
treatments. Medical testing affects a patient’s quality of life primarily in two ways: direct 
effects associated with the test or the testing process (either positive/negative) and benefits 
arising from clinical decisions made based on the test results. It is by capturing these effects 
that the true value of a test can be determined. This is a difficult undertaking, but innovators 
are encouraged to start engaging with clinicians early in the development process in order to 
delineate the pathway(s) for the new test and also to gain an understanding of issues that are 
likely to be important to patients (referred to as “patients’ perspective” in this study, and 
“perspective” does not refer to the classical definition as used in economic evaluation). An 
in-depth understanding of the care pathway is key to understanding the optimal placement 
and role (the chosen role of a new test implies the necessary properties it should possess) of a 
test on the care pathway and identifying key outcomes to be include in the evaluation.      
[Please insert Figure 1 here]  
Figure 1 shows the various phases on the medical technology innovation pathway and the 
stages at which economic analyses are conducted (i.e., early and late phases). The early phase 
comprises the concept stage and the early development stage. The concept stage is the 
discovery and ideation phase. In the case of medical tests, the test is still hypothetical at this 
point with no available data on test parameters (e.g. accuracy, cost, etc.). The early 
development phase occurs between the end of the concept stage and the equivalent of the 
Phase I stage of clinical trials of drugs. It involves the assessment of certain test properties 
and some form of experimental data may be available at this stage. 
In health care systems worldwide, economic evaluations are usually conducted at the late 
stage of product development [4], for example after Phase III drug trials (Figure 1). The 
rationale being that this is the point at which there is sufficient product-specific data for their 
proper evaluation [5]. In the case of medical tests, test performance would be assessed at the 
preclinical stages, test accuracy examined in phases 1 and 2, and clinical effectiveness 
assessed in phases 3 and 4 [6] (Figure 1). Coverage and reimbursement decisions are 
therefore made on tests at the time when substantial resources have already been committed 
to their research and development; thus, any negative coverage and reimbursement decisions 
would lead to no returns on investment and a loss being incurred (loss to manufacturers; 
opportunity cost for research; and inefficient use of Health Technology Assessment 
resources) [7,8]. Furthermore, advances in medical technology typically occur more rapidly 
than for drugs [9], and so leaving an economic evaluation to the late stages of development 
may make any new findings redundant. Thus, there is now an increasing interest in the 
economic analyses of medical tests at their early phases of development by investors, 
innovators, and policy makers, to identify their potential economic value and likely impact 
[10,11]. 
The early economic evaluation of a medical technology is defined as an iterative economic 
evaluation process to assess its economic value and likely impact [11], and is applied in its 
development process at a point where it can still be considered experimental or emerging [8]. 
In the case of medical tests, this is usually from the concept stage up to stage I clinical trials 
[12] and provides useful information that informs investment and design decisions under 
conditions of high uncertainties before the clinical performance of the test is established [4]. 
A key characteristic of early economic evaluation is the use of limited data which is 
associated with increased uncertainty and is likely to be more pertinent for tests [13,14]. If 
there is a considerable amount of uncertainty associated with data, as will be the case for the 
early economic evaluation, value of information (VOI) analysis  is essential [15]. This 
provides an analytic framework for decision makers to decide whether evidence is 
sufficiently robust to recommend investing into the further development of a test or not, and 
if not, identify specific areas where further information is needed to decide on further 
development decisions [16]. This will enhance the efficient use of limited resources and 
potentially reduce the risk of investing in a test which is not economically viable. 
Furthermore, the ubiquitous existence of uncertainty in parameter estimates and model 
structure at the early stage warrants the need to include extensive sensitivity analysis to test 
the robustness of parameter estimates, determine the range of parameters which have the 
greatest impact on cost-effectiveness, and determine how sensitive the results are to changes 
in model structure [17]. Another key issue is the “maximum cost” at which the index testing 
strategy is still cost-effective at a given willingness-to-pay threshold. The headroom approach 
is a simple but very useful method that provides the framework for estimating this value 
(known as the headroom) [18]. Although the analysis is done at the early development stage, 
the rationale is that eventually when the test is fully developed, its cost-effectiveness will be 
assessed at a giving willingness-to-pay threshold (for example £20-30,000) in the UK, thus 
the headroom is estimated at that threshold. Estimated headroom provides valuable 
information to support decision making on the feasibility of further test development and its 
consideration at the early stages especially at the concept stage will promote efficiency (i.e., 
if estimated headroom is too low, and realistically it is not possible to develop the new test 
below this level, resources should not be committed to its further development).   
Early economic evaluation of medical tests has potentially profound advantages for both 
decision makers and innovators. For decision makers, the early identification of the economic 
value and likely impact of new tests could help allocate limited budgets more efficiently by 
identifying which tests to fund for further development and which tests to reimburse on 
condition of further data collection (known as “coverage with Evidence Development” as 
practiced in the USA and UK). Furthermore, early economic analyses studies speed up 
decision making regarding test adoption in the late phase of development and support the 
management of test diffusion through “horizon scanning”: the early identification of new 
economically viable medical devices [8]. Early economic evaluation is becoming 
increasingly important as there is a growing demand to demonstrate value for money; 
however, there is little specific guidance on their implementation [11]. Early evaluations are 
more iterative in nature and conducted at a time where there is much less available data 
compared to the late phase of test development [10]. This is compounded by the fact that tests 
are indirect in terms of their impact on patients, therefore data on accuracy and downstream 
consequences may only be obtained from mapping clinical pathways resulting in potentially 
more uncertain data. These differences suggest that the methods used in the analysis of late 
economic evaluation need modification for use in early evaluation. The question therefore 
arises, how have economic evaluations conducted during the early phases of test development 
been done to date, and can any lessons be learnt from them? To identify the current practice 
in this field requires an up to date and focussed review of previous early economic 
evaluations of medical tests.  
The aim of this systematic review was to examine the methodologies and tools that have been 
employed in early economic evaluation studies of medical tests, specifically to:  
1) Gain a greater understanding of how the problem of insufficient data for model 
parameterisation has been resolved. 
2) Understand whether and how testing pathways have been modelled. 
3)  Examine whether sensitivity analysis has acknowledged the uncertainty that accompanies 
early modelling and the stage at which it has been undertaken. 
2.0 METHODS 
The following databases were searched for any studies published from inception to July, 
2016. 
I. Cochrane Library (CENTRAL) 
II. Medline  
III. EconLit  
IV. Centre for Reviews and Dissemination [Database of Abstracts of Reviews of Effects 
(DARE), Heath Technology Assessment (HTA), and NHS Economic Evaluation 
Database (NHS EED)] 
V. Health Management Information Consortium (HMIC) 
VI. Excerpta Medica dataBASE (EMBASE) 
Internet searches were also conducted (e.g., Google scholar and the websites of organisations 
related to innovations in health care such as EuroScan) to identify any grey literature. The 
nature of early economic evaluations means that it is unlikely to be published. Therefore, 
medical technology companies (7) were contacted to identify unpublished evaluations to 
complement the literature review, but all efforts proved futile.  The reference list of the 
relevant articles included in the review were scanned for additional relevant articles. The list 
of articles used was managed through the reference management software, Endnote.  
2.1 Search terms    
The search strategy was customized for each database and used a combination of MESH 
terms and index terms as shown in Table 1. The search strategy was developed in 
consultation with an information specialist and piloted to ensure that all relevant studies were 
retrieved. The complete search strategies including how the different question elements were 
combined are illustrated in Table 2. 
[Please insert Table 1 here] 
[Please insert Table 2 here] 
2.2 Inclusion criteria 
Primary studies were deemed potentially relevant to be included in the review if they were: 
1. An economic evaluation conducted at the early phases of a medical test development. 
2. The evaluated technology was a medical test or series of tests used together (at least one 
test needed to be present in at least one arm of the analysis). 
2.3 Exclusion criteria 
Articles were excluded from the review if they were: 
1. Trial protocols or commentaries. 
2. Letters or editorials.  
2.4 Selection of articles for the review 
After the removal of duplicates, a 2-stage screening of titles and abstracts followed by full 
text articles was undertaken against the inclusion criteria by two reviewers (S.F. and P.B.) 
independently. Disagreements regarding study eligibility were resolved using the opinion of a 
third reviewer (C.D.) where necessary. All studies identified after the second stage of article 
selection were subsequently considered for data extraction. 
2.5 Data extraction 
Data extraction was conducted by (S.F. and A.S.) for each study included in this review to 
answer the following questions: 
• How was the problem of an early analysis not having sufficient data for model 
parameterisation resolved? 
– What sources (type) of data were used? 
– Was the source (type) of data used influenced by the stage of evaluation? 
• Modelling of testing pathways  
– What type of model was used in modelling disease progression and the testing 
pathways (e.g. Decision tree, Markov)? 
– Did the studies consider test accuracy and all possible test results (i.e. true positives 
(TP), true negatives (TN), false negatives (FN), and false positives (FP))? 
– Did the analysis include all the issues important to patients on the test-treat pathway 
(e.g., personal costs incurred when accessing testing, effect of testing pathway on 
quality of life)? 
– Was headroom analysis included, and at what stage of the analysis?  
• Uncertainty  
– Did sensitivity analysis acknowledge the uncertainty that accompanies early 
modelling? 
– Was value of information (VOI) analysis conducted? 
2.6 Quality assessment  
The methodological quality of the included studies was assessed using a 10-point checklist 
for economic evaluations [19], and a score was assigned based on how well criteria were met; 
scores of 1, 0.5 and 0 were assigned to “yes”, “cannot tell” and “no” respectively. Thus, each 
study scored from 0 (worst) to 10 (best) [20]. However, because the focus of this systematic 
review was to explore methodologies used and not to comment on the validity of results and 
conclusions drawn from these studies, no study was rejected on quality grounds. It is worth 
mentioning that one of the main issues when scoring the quality of publications is how to 
weight each item to provide an overall quality score. The quality issues raised by different 
clinical topics differs. There is no objective way of doing this, thus, one has to be cautious 
since items are not always equivalent. Different methods are likely to produce different 
scores and in some cases scoring might even bias quality assessment. However we do not 
think the potential limitations of quality scores are applicable to this study as assessment of 
quality was concerned with the presence or absence of a methodological approach and not the 
effect of an approach on outcome measure. 
3.0 RESULTS 
After de-duplication, 4,494 unique articles were identified for title and abstract screening. 88 
titles and abstracts were potentially eligible for inclusion. After full text screening, and 
unsuccessful attempts to contact medical technology companies, manufacturers of the 
technologies identified from the EuroScan website and obtain full text of conference 
abstracts, five studies were included for narrative synthesis. The PRISMA diagram (Figure 2) 
illustrates the results of the screening process with reasons for exclusion noted. 
[Please insert Figure 2 here]  
[Please insert Table 3 here] 
3.1 Characteristics of included studies 
Table 3 illustrates the characteristics of the studies included in this review which were 
published between 2005 and 2016 [21-25]. Two studies were conducted in the Netherlands 
[23,25] and three studies were conducted in the USA [21,22,24]. The clinical conditions 
explored spanned a range of disease areas, namely rheumatoid arthritis, persistent asthma, 
chlamydia trachomatis, peripheral artery disease, and coronary artery disease. All studies 
stated the intended applications of the tests under consideration: these being diagnosis, 
predicting a response to treatment, screening, and risk assessment. Four studies were 
conducted at the early development stage (Figure 1) [22-25] and one study was conducted at 
the concept stage [21]. Model-based approaches were used in cost-utility [21,23,24,25] and 
cost-effectiveness analyses [22]. Four studies were conducted from the societal perspective 
[21,23,24,25] and one study was conducted from the public healthcare perspective [22]. 
Three studies adopted a time horizon of ≤ 10yrs [22,24,25], one study adopted a lifetime time 
horizon [23], and one study did not incorporate a time horizon [21] 
3.2 Quality assessment of included studies 
Based on the quality assessment criteria applied, two studies had a score of 8.5 [22,25], two 
studies had a score of 8 [23,24] and one study had a score of 7 [21] (Table 4). All studies lost 
a point each for not giving a comprehensive description of the testing strategies and therefore 
provided insufficient information about the clinical pathway, making it difficult to tell 
whether any important alternatives were omitted from the studies [21-25].Three studies lost a 
point each for not identifying and including all important outcomes for each alternative (such 
as those from the patient’s perspective) [21,23,24]. One study lost a point because it was not 
clear whether cost and consequences were adjusted for differential timing. And whether they 
were valued credibly because all the data used were based on assumptions but no information 
on the basis of the assumptions was provided [21]. It is worth mentioning that due to word 
count restriction not all the clinical information can be incorporated in economic evaluations. 
Usually and especial for piggy-bag evaluations, these have to be read together with clinical 
publications to get an impression of the total available evidence on a topic or research 
question for evaluation. In this study, this was done before and during quality assessment to 
ensure an effective assessment.       
[Please insert Table 4 here] 
3.3 Data extraction 
3.3.1 How was the problem of an early analysis not having sufficient data 
for model parameterisation resolved? 
To populate the index testing strategy arm of the models, several sources of data were used 
across the different studies from four main perspectives (test accuracy, costs, measures of 
effectiveness and transitional probabilities describing the disease states) as shown in Table 5, 
and these were found to be influenced by the stage of evaluation/analysis.  
[Please insert Table 5 here] 
One study was conducted at the concept stage [21] and all data used were based on 
assumptions. Interestingly, no information on what these assumptions were based was 
provided. Sources of data describing the test accuracy estimates, costs, measures of 
effectiveness and transitional probabilities varied across studies conducted in the early 
development stage (Table 5). It is noted that, in all these studies, the plausibility of the 
estimates and the robustness of the results obtained by employing these estimates were 
examined in sensitivity analysis. 
3.3.2 Modelling of testing pathway 
3.3.2.1 What type of model was used in modelling disease progression and the testing 
pathways?  
Three studies used a Markov state transition model [21,23,24], one study used a decision tree 
[22] and one study used both the decision tree and Markov model [25]. The Markov models 
covered the disease and the decision trees covered the testing pathways. Information was 
provided to justify the model structure in only three studies [23-25]. 
3.3.2.2 Did the studies consider test accuracy and all possible test results? 
Four studies modelled explicitly each of the possible test results [21,22,24,25]. One study 
only considered TP and TN, and assumed a perfect biomarker; however, no information was 
given on what the consequences of test errors would be for this test [23]. In one study, the 
first year of the 5-year time horizon was modelled as a decision tree with chance nodes at 6 
and 12 months (as repeated testing is part of the clinical pathway) to classify patients as TP, 
FP, TN and FN with those classified as TP or FN at 12 months entering the patient level state 
transition model and followed for 4 years [25]. In another study, four subpopulations based 
on the test result of TP, FN, TN and FP were considered within the same model [24].  
3.3.2.3 Did the analysis include all the issues important to patients on the test-treat 
pathway?   
It is notable that of the four studies that were conducted from the societal perspective, only 
one study acknowledged and included some issue on the test-treat pathway that may be 
relevant to the patient [25]. In the other studies, the issue of the patient perspective was 
ignored [21,23,24]. In Buisman et al [25], follow-up visit costs and productivity costs (which 
was defined as the number of days that a patient with a paid job was absent from work) were 
included. The study by Huang et al [22] considered the effects of how long patients were 
willing to wait to obtain their test results. This seems reasonable as the study was conducted 
from a public health care perspective and one of the key mechanisms by which the test in this 
study might impact on outcomes is being able to treat patients at the time they present to 
prevent onward transmission of infection. Indeed, in this study, one-way sensitivity analyses 
demonstrated that one of the key parameters driving the results of the cost-effectiveness 
analysis was how long patients were willing to wait to obtain their results. This was because a 
short processing time reduced the time between testing and treatment thereby increasing 
treatment rates and subsequent improvement in the quality of life of patients at a population 
level. 
3.3.2.4 Was headroom analysis included, and at what stage of the analysis? 
Headroom analysis was included in the two studies conducted in the Netherlands [23,25]. It is 
noted that neither of these studies was conducted at the concept stage of development but at 
the early development stage when there was some data available to describe the test 
parameters. Thus, headroom analysis was included at the early development stage but not the 
concept stage.  
3.3.3 Uncertainty 
3.3.3.1 Did sensitivity analysis acknowledge the uncertainty that accompanies early 
modelling? 
In all studies, the issue of a lack of data and the simplification of models to represent reality 
were acknowledged as study limitations. To deal with these limitations, extensive sensitivity 
analysis was undertaken on all important parameters (e.g., sensitivity analysis of test 
accuracy) to evaluate the influence of uncertainty on model predictions. Probabilistic and 
deterministic sensitivity analyses were conducted in four studies [22-25] and deterministic 
sensitivity analysis was conducted in one study [21].  
3.3.3.2 Was value of information (VOI) analysis conducted? 
Considering the importance and role of VOI analysis in supporting decision making under 
conditions of uncertainty (typically characteristic of early economic evaluation), it is notable 
that this was not conducted in any of the included studies. 
4.0 DISCUSSION 
Typically, economic evaluations are undertaken as a one-off exercise at the late stage of 
development of a new medical device [26]. Increasingly, several studies have indicated the 
importance of an iterative use of economic evaluation during the early phases of development 
of medical devices to identify their potential economic value and likely impact and to support 
and guide decision making under conditions of high uncertainty [27,28].  However, there is 
little specific guidance on their implementation to maximize the value and quality of such 
analysis.  This systematic review focussed on exploring the approaches used in early 
economic evaluation of medical tests. Five studies were identified and data was extracted 
from these studies to gain insight into how the problem of an early analysis not having 
sufficient data for model parameterisation has been resolved, understand whether and how 
testing pathways have been modelled, and examine whether sensitivity acknowledged the 
uncertainty that accompanies early modelling.  
The major issue associated with test evaluation is the rather difficult connection between the 
test and final health outcomes. The evaluation of tests has typically been restricted to test 
accuracy (sensitivity and specificity) an intermediate outcome measure; which may influence 
but do not directly determine patient relevant outcomes. However, for economic evaluation of 
tests, we need to know the longer term costs and effects of the test-treat pathway: patient 
outcomes dependent on test results. This usually involves extensive modelling of delineated 
test-treat pathways. This is difficult enough to do for an established test, but for a new test it 
is even more complex and difficult because pathways may not be defined. This may be a 
plausible reason why there are so few publications on early test evaluation and thus the small 
number of studies identified and included in this study.          
To resolve the issue of an early analysis not having sufficient data for model 
parameterisation, studies in this review relied on different sources of data and the source of 
data used was influenced by the stage at which the analysis was conducted (concept stage or 
early development stage). One study was conducted at the concept stage and, as expected, the 
relevant data on test accuracy, costs, measures of effectiveness and transitional probabilities 
of the index testing strategy were all based on assumptions. However, the basis for these 
assumptions was not stated, making these estimates somewhat arbitrary and weakly 
informed, although their plausibility and robustness were extensively examined in sensitivity 
analyses. Four studies were conducted at the early development stage, yet, within the 
confines of this stage of evaluation, diverse sources of data were used to inform the new 
testing strategies across the different studies. This observation is explained by the fact that the 
tests were at various stages of development even within the early development stage; hence, 
different levels of data were available specific to different tests. For example, in one study, 
the test was in an experimental phase and primary data were available for most parameters 
for the analysis. In other studies, primary data were not available for all parameters; hence 
other plausible sources of data including expert opinion and secondary sources were relied 
upon to supplement primary data (making investigation of uncertainty particularly 
important). The plausibility and robustness of the estimates were however examined in 
sensitivity analyses and their effects on the conclusions drawn from the models examined.  
Test accuracy was considered in all five studies and four studies modelled explicitly each of 
the possible test results. This meant that the full implications of test accuracy on the model 
results could be examined in the analysis. In the study that did not model each of the test 
results, this meant that it was not possible to determine the consequences of test errors. 
However, it is notable that even though a societal perspective was adopted in four studies, 
only one of these four considered aspects of the test-treat pathway that may be important to 
patients. This is important because patient perspectives can have a significant impact on the 
conclusions drawn from a model. For example, in one study, one of the key parameters 
driving the results of the cost-effectiveness analysis was how long patients were willing to 
wait to obtain their test results. Overlooking this important parameter in this particular 
analysis would have led to misleading conclusions. The issue of the timing of test results 
(rapid tests) is probably the most obvious (and most studied) way in which a test might 
produce benefits aside from improvements in accuracy [22]. However, it is important to 
stress that other aspects such as test acceptability to patients and professionals, procedural 
harms or benefits of the testing process etc., should also be considered [29,30].  
Headroom analysis was included in two studies, and it was noted that neither of them was 
conducted at the concept stage of development. However, in the headroom paradigm, 
assumptions can be made at the concept stage for a preliminary assessment of whether a test 
warrants further development first. Later, in the early development stage when more evidence 
becomes available, this can then be updated to determine the headroom in the face of newly 
available evidence. This reduces the risk of investing in a bad technology. Though it might be 
argued that if a project is terminated at the early development stage, not many resources 
would have been invested, it is equally true that, if the headroom had been established at the 
concept stage, the invested resources could have still been used efficiently elsewhere. 
Headroom analysis has potential in the early economic evaluation of tests to promote 
efficiency at the beginning of the test development process.  
Sensitivity analysis is important in early economic evaluations where there is not enough 
device-specific data, and initial model parameter estimates may have to be derived from data 
sources associated with high levels of uncertainty. The emphasis here is whether sensitivity 
analysis acknowledges the uncertainty associated with early evaluation and the early stage at 
which it is conducted. All the studies reviewed acknowledged the uncertainty associated with 
data used in their analysis: extensive sensitivity analyses were performed on important 
parameters to evaluate the influence of uncertainty on model predictions. However, it is 
notable that VOI analysis was not conducted in any of the included studies, meaning that no 
insights into the value of future research were obtained. Thus there was the possibility of 
drawing incorrect conclusions from the results about whether to further fund the development 
of a new testing strategy or not based on the evidence used. This could have been because the 
studies were conducted at a time when VOI was not well established as a concept or it was 
deemed irrelevant.  
4.1 Limitations of the research 
Few studies were found to be eligible to be included in the review. Furthermore, studies were 
conducted to answer different research questions, so it was not possible to compare their 
results. There is no existing quality assessment tool specifically to evaluate an economic 
evaluation focussed on testing (which requires development of a novel tool). 
4.2 Recommendations 
To improve future practice, and based on the study findings, the following recommendations 
for early economic evaluations focussed on testing conducted in the future are made:  
• To fully capture the potential effects of testing on patient relevant outcomes and thus the 
potential health economic impact of tests, it is crucial that the assessment of the outcomes 
of testing goes beyond health and specific payer perspectives to acknowledge and include 
issues on the testing pathway that may be relevant to patients (including anxiety, 
acceptability, and loss of income). This will mitigate against over- or underestimating the 
true value of tests in early modelling studies and thereby appropriately inform decision 
making. 
• All possible test results and their subsequent patient pathways should be described in a 
model to ensure that the full implications of test accuracy are considered in the analysis.  
• Extensive sensitivity analyses of all important parameters should be undertaken to 
evaluate the influence of uncertainty on model predictions. 
• The potential adoption of VOI should be considered. This can be beneficial in mitigating 
against drawing wrong conclusions from study results to fund the further development of 
a new testing strategy based on the available evidence used. 
• Headroom analysis has potential to provide important insights into the viability of 
developing new tests and should be considered at the early stages of test development, 
especially at the concept stage to promote efficiency at the start of the test development 
process. 
4.3 Suggestions for future work 
The review has shown that some of the methods proposed (VOI and Headroom analysis) are 
not being used. Is there a need to refine/develop these methods for the specific context of 
early economic evaluation of medical tests? Or are other tools needed? To answer these 
questions, further research is needed in this field. Currently, there is no existing quality 
assessment tool specifically to evaluate an economic evaluation focussed on testing. Medical 
test evaluation is complex (tests are indirect in terms of their impact on patients) and differs 
from the evaluation of treatments. Thus, there is the need to develop a tool to capture such 
complexities if the methodological quality of economic evaluations focussed on testing is to 
be properly assessed. For example, the development of a checklist could prompt 
consideration of the ways in which tests might impact on patients (aside from accuracy). 
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Expert commentary   
In an increasingly resource-constrained environment, early economic evaluation of medical 
tests has potentially profound advantages for both decision makers and innovators as the 
demand to demonstrate value for money increases. The early assessment of the potential 
economic value and likely impact of a test enhances more informed decision making that 
could potentially guarantee successful implementation in the future. However, there is little 
specific guidance on their implementation and there is no consistent approach on the 
methodologies and tools to be used. For early economic evaluation to become a practical tool 
there is the need for concerted efforts to develop rigorous methodology in this growing field 
to maximize the value and quality of such analysis. 
Five-year view  
The growing demand to demonstrate value for money is likely to be associated with an 
increase in the use of economic evaluation at the early phases of medical test development. 
With the limited guidance available on their implementation, it is expected that the 
inconsistent use of methods in the early economic evaluation of medical tests will continue. 
However, with the publication of additional studies highlighting the need for the development 
of rigorous methodology in this growing field, there will be an increase in awareness among 
researchers. We expect that this will lead to an increase in the effort to develop rigorous 
methodology to maximize the value and quality of such analysis.       
 
Key issues 
• There is an increasing interest in the adoption of early cost-effectiveness modelling for 
test evaluation. However, there is little specific guidance on their implementation. 
• The results revealed that there is heterogeneity in the approaches used in this growing 
field. The perspective of patients and the potential for value of information (VOI) to 
provide information on the value of future research is often overlooked. 
• Test accuracy is an essential consideration, with most studies having described and 
included all possible test results in their analysis, and conducted extensive sensitivity 
analyses on important parameters.  
• Headroom analysis was considered in some instances but at the early development stage 
(not the concept stage).  
• There is the need for concerted efforts to develop rigorous methodology in this growing 
field to maximize the value and quality of such analysis. 
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